Explore the details of the Boehringer Ingelheim Pharmaceuticals Inc. v. USV Private Limited case under case number 1:25cv00862 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:25cv00862
Filing Date
Jul 10, 2025
Cause of Action
Patent Infringement
Status
-
Case Link
View Case
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Boehringer Ingelheim Pharma GmbH & Co. KG -
USV Private Limited -

Patents Involved in the Case

This case involves 5 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Jul 10, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025COMPLAINT for Patent Infringement filed against USV Private Limited (Filing fee $ 405, receipt number ADEDC-4731290) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Attachments: # 1 Exhibits A-D, # 2 Civil Cover Sheet)(scs) (Entered: 07/11/2025)PACER Document
Jul 11, 2025Summons Issued as to USV Private Limited on 7/11/2025. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, and Boehringer Ingelheim Pharmaceuticals Inc., filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,551,957 B2; 11,090,323 B2; 11,833,166 B2; 12,115,179 B2. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 30, 2025. Date of Expiration of Patent(s): October 14, 2029, February 11, 2030, April 3, 2034.Thirty Month Stay Deadline: 11/30/2027. (scs) (Entered: 07/11/2025)PACER Document